MDXHNasdaqServices-Medical LaboratoriesUS GAAP · USD

MDxHealth SA

MDxHealth SA is a molecular diagnostics company focused on tests for prostate cancer and other urologic diseases. The company develops and commercializes proprietary genomic, epigenomic, exosomal, and related assays through its laboratory operations in the United States, while the parent company is domiciled in Belgium.

Ask about the company
Revenue108m USD
+19.8 %y/y
Operating profit (EBIT)-23.8m USD
+21.0 %y/y
EBIT margin-22.0%
+11.4 ppy/y
Net income-33.5m USD
+12.0 %y/y
Free cash flow-3.3m USD
+83.8 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

-50050100150m USD2022: 37 m USD2022: EBIT -41 m USD20222023: 70 m USD2023: EBIT -38 m USD20232024: 90 m USD2024: EBIT -30 m USD20242025: 108 m USD2025: EBIT -24 m USD2025108-24
RevenueOperating profit (EBIT)

Business

Share of revenue
Prostate cancer diagnostics65 %

Clinical tests used to help diagnose and assess prostate cancer.

Urologic disease diagnostics25 %

Tests supporting diagnosis and prognosis across other urologic conditions.

Molecular technology platforms10 %

Underlying genomic, epigenomic, and exosomal technologies used in the test menu.

Customers

MDxHealth sells to physicians and clinical practices that need actionable molecular information to guide diagnosis and treatment decisions. Its core end market is urology, especially providers managing prostate cancer and related diseases, where test results can help refine patient risk assessment and care pathways.

Urology practices

They buy molecular tests to support diagnosis and management of prostate and other urologic diseases.

Physicians and specialist clinics

They use the test results to inform risk stratification, prognosis, and treatment selection.

Health systems and laboratories

They access testing through laboratory workflows and referral channels for specialty diagnostics.

Patients

They are the end beneficiaries of the tests, though purchasing is mediated by clinicians and payers.

Strategy

The company’s strategy centers on expanding its sales channel and broadening its test menu for the urology customer base. It is also focused on operating discipline and laboratory commercialization so that growth in molecular diagnostics translates into a stronger recurring testing business.

Grow urology sales channelShort term

A wider commercial footprint increases test orders and supports repeat usage by specialists.

Broaden menu offeringMedium term

A larger portfolio helps capture more of each customer relationship and supports cross-sell.

Improve operating disciplineShort term

Laboratory diagnostics requires disciplined execution to support scale and consistency.

Geography

MDxHealth is domiciled in Belgium but operates laboratory activities in the United States, which is the key commercial and clinical market referenced in the reports. The business is therefore exposed to U.S. healthcare reimbursement, provider adoption, and regulatory dynamics, while its corporate structure remains Belgian.

Risks

MDxHealth is exposed to physician adoption risk, since demand depends on clinicians choosing its tests and integrating them into care pathways. It also faces reimbursement, regulatory, and competitive risks common to molecular diagnostics, along with execution risk in laboratory operations and product menu expansion.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Reimbursement and pricing pressure1Physician adoption and referral concentration2Regulatory and laboratory compliance3Competitive pressure4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Reimbursement and pricing pressureImpact: HighLikelihood: High

    Molecular diagnostics often rely on payer coverage decisions that can affect test volume and realized pricing.

    Exposure: U.S. healthcare payers

  2. Physician adoption and referral concentrationImpact: HighLikelihood: Medium

    Revenue depends on urologists and related specialists ordering tests and using them in clinical practice.

    Exposure: Urology end market

  3. Regulatory and laboratory complianceImpact: HighLikelihood: Medium

    Clinical testing businesses must maintain quality systems, licenses, and compliance standards.

    Exposure: U.S. laboratory operations

  4. Competitive pressureImpact: MediumLikelihood: High

    Other diagnostic providers can target the same prostate cancer and urology workflows.

    Exposure: Precision diagnostics market

Accounting

Judgemental items
Testing revenue recognition

Clinical testing revenue may require estimates around service timing and payer collections.

Impact: Can affect reported revenue and receivables

Earnout liabilities

Acquisition-related contingent payments create cash flow and valuation judgments.

Impact: Affects financing and investing cash flows

Intangible asset and goodwill impairment

Acquired diagnostics assets must be tested for recoverability if performance changes.

Impact: Can create material non-cash charges

Lease accounting

Laboratory and office leases create right-of-use assets and lease liabilities.

Impact: Affects leverage metrics and expense recognition

Similar listed companies

Publicly listed companies with a comparable business focus.

Insight Molecular Diagnostics Inc.

IMDX · In Vitro & In Vivo Diagnostic Substances

IDEXX Laboratories, Inc

IDXX · In Vitro & In Vivo Diagnostic Substances

GeneDx Holdings Corp.

WGS · Services-Health Services

MBX Biosciences, Inc.

MBX · Pharmaceutical Preparations

Aditxt, Inc.

ADTX · Pharmaceutical Preparations

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

Last updated: 28/09/2026